Solensia is a once-monthly, injectable monoclonal antibody therapy for the control of feline osteoarthritis (OA) pain

  • 77 % of cat owners reported improvement in signs of pain when their cats were treated monthly with Solensia in a 3-month study
  • Controls the pain of OA in cats, helping to improve their mobility, comfort and well-being1
  • Solensia was found to be well tolerated in field studies that included cats identified as IRIS stage 1 or 21†‡
injectable-solution-updated injectable-solution-updated injectable-solution-updated

67% of cat owners experienced improvement in signs of their cat's pain in the placebo group.

Total N = 131 of 267 treated cats were identified as IRIS stage 1 or 2

First To Know Thumbnail First To Know Thumbnail First To Know Thumbnail

Be the 1st to know when Solensia is available

Add your email to the list for updates about this innovative, new product for cats!

One monthly injection controlled pain, increasing mobility1

Solensia is administered monthly at the veterinary practice

ABOUT SOLENSIA

A Breakthrough in OA Pain Treatment

Solensia is the first and only once-monthly monoclonal antibody therapy that controls feline osteoarthritis (OA) pain. Solensia is administered in the clinic.

Targets nerve growth factor (NGF) to control pain

77% of cat owners reported improvement in signs of pain when their cats were treated monthly with Solensia in a 3-month study

Controls the pain of OA in cats, helping to improve their mobility, comfort and well-being1

Functions like naturally occurring antibodies

67% of cat owners experienced improvement in signs of their cat's pain in the placebo group.

MECHANISM OF ACTION

Solensia Works Differently Than NSAIDs

MOA MOA MOA

Solensia is a monoclonal antibody (mAb)

  • It is a highly specific protein targeting molecules involved in disease3
  • It functions like naturally occurring antibodies—it is eliminated via normal protein degradation pathways, with minimal involvement of the liver or kidneys4

Solensia binds to Nerve Growth Factor (NGF), and its action helps to:5

  • Control pain
  • Limit the release of proinflammatory mediators and more NGF
  • Lower neurogenic inflammation

In osteoarthritic joints, NGF is elevated.6 Solensia reduces the negative impact NGF has in osteoarthritic joints.

See how it works

EFFICACY

Efficacy Your Cat Patients Need

Reducing pain helps improve the quality of life for your cats.7 Solensia has been demonstrated to effectively control OA pain with a monthly injection.

In clinical field studies, Solensia effectively controlled pain associated with feline osteoarthritis, and is delivered in-clinic as a subcutaneous (SC) injection.


study-days-graph-updated study-days-graph-updated study-days-graph-updated
Successful Pain Control

Three out of four cats benefitted from successful pain control over 3 months, in a pivotal trial using client reported improvement.**

weeks-of-studygraph-updated weeks-of-studygraph-updated weeks-of-studygraph-updated
Helps to Improve Mobility1

A pilot study found 12.9% greater activity in cats administered Solensia versus a placebo. This increase in activity was demonstrated in the first 3 weeks of the study in cats with DJD-associated pain using objective (and subjective) measurement.


**Client-specific outcome measures (CSOM) is a tool used to assess pain and pain treatment. It measures the impact of pain on the individual cat, including physical activity level, sociability, and quality of life.

67% of cat owners experienced improvement in signs of their cat's pain in the placebo group.

SAFETY

Safety for Cats

Functions like naturally produced antibodies

Solensia is eliminated via normal protein degradation pathways—just like naturally produced antibodies—with minimal involvement of the liver or kidneys4

Solensia was shown to be well tolerated

The most commonly reported adverse events in field studies were vomiting and injection site pain

Well-tolerated at 5X the label dose

Clinical safety studies showed that Solensia given at 5X the highest label dose every 4 weeks for 6 months was shown to be well-tolerated

Allows more cats to be treated for longer

In clinical studies, Solensia was demonstrated to be a long-acting and well-tolerated pain medication, allowing more cats with OA pain to be treated for longer durations

DOSAGE AND STORAGE

Take Control of Managing OA Pain

Dose:

1 mL for cats
5.5 - 15.4 lbs

2 mL for cats
15.5-30.8 lbs

Administration:
  • Cats should be dosed by weight range according to the dosing chart
  • Cats are given the full content of 1 or 2 vials based on body weight to target a minimum dosage of 0.45 mg/lb (1.0 mg/kg) body weight, administered subcutaneously once a month. Aseptically withdraw the total dose into a single syringe and administer immediately
  • If a vaccine is to be administered at the same time as treatment with frunevetmab, the vaccine should be administered at a different site to that of frunevetmab administration
  • Avoid excessive shaking or foaming of the solution
Storage:
  • Store upright in a refrigerator, between 35° to 46°F (2° to 8°C). Do not freeze
  • Protect from light
  • Once opened, contents of the vial should be used immediately and any remaining solution should be disposed

read-dosing-updated read-dosing-updated read-dosing-updated

Read Dosing and Administration Guides

month month month

“Once a month is better than trying to give my cat something once a day.”

“This is great, it’s once-a-month, less stress than two times a day.”

Pet Owner Reactions to Product Profile2

back-where-i-belong

Get notified when Solensia is available

tips-for-examination-updated

View tips forexamining cats for OA

resources-graphic-updated

Find resources to screen for OA pain

cat-osteoarthritic-updated

Get an OA checklist for your clients

References

  1. Gruen ME, Myers JAE and Lascelles BDX (2021) Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study. Front. Vet. Sci. 8:610028. doi: 10.3389/fvets.2021.610028.
  2. Zoetis Market Research: KG MarketSense, 2018.
  3. Olivry T, Bainbridge G. Advances in veterinary medicine: therapeutic monoclonal antibodies for companion animals. Clinician’s Brief. Published March 2015.
  4. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507.
  5. Enomoto M, Mantyh PW, Murrell J, Innes JF, Lascelles BDX. Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. Vet Rec. 2019;184(1):23.
  6. Isola M, Ferrari V, Miolo A, Stabile F, Bernardini D, Carnier P, Busetto R. Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteorarthritis. Vet Comp Orthop Traumatol. 2011;24(4):279-284.
  7. Monteiro BP, Steagall PV. Chronic pain in cats: Recent advances in clinical assessment. Journal of Feline Medicine and Surgery. 2019;21(7):601-614. doi:10.1177/1098612X19856179.

SLN-00004

IMPORTANT SAFETY INFORMATION:

See full Prescribing Information. For use in cats only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Solensia should not be used in breeding cats or in pregnant or lactating queens. Solensia should not be administered to cats with known hypersensitivity to frunevetmab. The most common adverse events reported in a clinical study were vomiting and injection site pain.

IMPORTANT SAFETY INFORMATION:

See full Prescribing Information. For use in cats only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Solensia should not be used in breeding cats or in pregnant or lactating queens. Solensia should not be administered to cats with known hypersensitivity to frunevetmab. The most common adverse events reported in a clinical study were vomiting and injection site pain.